Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 50 articles:
HTML format
Text format



Single Articles


    May 2017
  1. YU ZH, Lun SM, He R, Tian HP, et al
    The dual function of MAZ mediated by FOXF2 in basal-like breast cancer: Suppression of progression but promotion of proliferation.
    Cancer Lett. 2017 May 31. pii: S0304-3835(17)30356.
    PubMed     Text format     Abstract available


    April 2017
  2. WU YH, Hong CW, Wang YC, Huang WJ, et al
    A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
    Cancer Lett. 2017 Apr 24. pii: S0304-3835(17)30283.
    PubMed     Text format     Abstract available


  3. LUI AJ, Geanes ES, Ogony J, Behbod F, et al
    IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
    Cancer Lett. 2017 Apr 12. pii: S0304-3835(17)30235.
    PubMed     Text format     Abstract available


    March 2017
  4. DESHMUKH SK, Srivastava SK, Zubair H, Bhardwaj A, et al
    Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes.
    Cancer Lett. 2017 Mar 13. pii: S0304-3835(17)30174.
    PubMed     Text format     Abstract available


  5. MONTEIRO FL, Vitorino R, Wang J, Cardoso H, et al
    The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.
    Cancer Lett. 2017 Mar 10. pii: S0304-3835(17)30171.
    PubMed     Text format     Abstract available


  6. LI Y, Li J, Zhang Y, Wang Y, et al
    Roles of Cancer/Testis Antigens (CTAs) in Breast Cancer.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30148.
    PubMed     Text format     Abstract available


    February 2017
  7. BURNETT JP, Lim G, Li Y, Shah RB, et al
    Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Cancer Lett. 2017 Feb 27. pii: S0304-3835(17)30132.
    PubMed     Text format     Abstract available


  8. ZHANG Z, Zhu Y, Wang Z, Zhang T, et al
    Yin-Yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30108.
    PubMed     Text format     Abstract available


    January 2017
  9. MONTAGNA E, Palazzo A, Maisonneuve P, Cancello G, et al
    Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
    Cancer Lett. 2017 Jan 26. pii: S0304-3835(17)30068.
    PubMed     Text format     Abstract available


  10. RESZKA E, Przybek M, Muurlink O, Peplonska B, et al
    Circadian gene variants and breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30035.
    PubMed     Text format     Abstract available


  11. BUI QT, Im JH, Jeong SB, Kim YM, et al
    Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Cancer Lett. 2017 Jan 18. pii: S0304-3835(17)30037.
    PubMed     Text format     Abstract available


  12. MENDOZA-RODRIGUEZ M, Romero HA, Fuentes-Panana EM, Ayala-Sumuano JT, et al
    IL-1beta induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30025.
    PubMed     Text format     Abstract available


  13. MUNZONE E, Colleoni M
    Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30026.
    PubMed     Text format     Abstract available


  14. HUANG R, Yu Y, Zong X, Li X, et al
    Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1alpha.
    Cancer Lett. 2017 Jan 13. pii: S0304-3835(17)30020.
    PubMed     Text format     Abstract available


    December 2016
  15. BHARTI R, Dey G, Banerjee I, Dey KK, et al
    Somatostatin Receptor Targeted Liposomes with Diacerein Inhibit IL-6 for Breast Cancer Therapy.
    Cancer Lett. 2016 Dec 23. pii: S0304-3835(16)30784.
    PubMed     Text format     Abstract available


  16. CAZZANIGA ME, Dionisio MR, Riva F
    Metronomic chemotherapy for advanced breast cancer patients.
    Cancer Lett. 2016 Dec 23. pii: S0304-3835(16)30782.
    PubMed     Text format     Abstract available


  17. MULUHNGWI P, Krishna A, Vittitow SL, Napier JT, et al
    Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
    Cancer Lett. 2016;388:230-238.
    PubMed     Text format     Abstract available


    November 2016
  18. KIM JY, Lee N, Kim YJ, Cho Y, et al
    Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation.
    Cancer Lett. 2016 Nov 25. pii: S0304-3835(16)30710.
    PubMed     Text format     Abstract available


  19. TU M, Li Z, Liu X, Lv N, et al
    Vasohibin 2 promotes epithelial-mesenchymal transition in human breast cancer via activation of transforming growth factor beta 1 and hypoxia dependent repression of GATA-binding factor 3.
    Cancer Lett. 2016 Nov 17. pii: S0304-3835(16)30704.
    PubMed     Text format     Abstract available


  20. ZYSK A, DeNichilo MO, Panagopoulos V, Zinonos I, et al
    Adoptive transfer of ex vivo expanded Vgamma9Vdelta2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Cancer Lett. 2016 Nov 16. pii: S0304-3835(16)30699.
    PubMed     Text format     Abstract available


  21. LIANG YK, Zeng, Xiao YS, Wu Y, et al
    MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERalpha expression and AKT activation.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30682.
    PubMed     Text format     Abstract available


  22. LIANG S, Chen Z, Jiang G, Zhou Y, et al
    Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kappaB/IL-6 signals.
    Cancer Lett. 2016 Nov 9. pii: S0304-3835(16)30681.
    PubMed     Text format     Abstract available


  23. JI X, Peng Z, Li X, Yan Z, et al
    Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
    Cancer Lett. 2016 Nov 7. pii: S0304-3835(16)30662.
    PubMed     Text format     Abstract available


    October 2016
  24. WANG X, Wei S, Zhao Y, Shi C, et al
    Anti-proliferation of breast cancer cells with itraconazole: hedgehog pathway inhibition induces apoptosis and autophagic cell death.
    Cancer Lett. 2016 Oct 31. pii: S0304-3835(16)30665.
    PubMed     Text format     Abstract available


  25. VENNIN C, Spruyt N, Robin YM, Chassat T, et al
    The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.
    Cancer Lett. 2016 Oct 22. pii: S0304-3835(16)30644.
    PubMed     Text format     Abstract available


  26. KIKUCHI M, Katoh H, Waraya M, Tanaka Y, et al
    Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer.
    Cancer Lett. 2016 Oct 15. pii: S0304-3835(16)30629.
    PubMed     Text format     Abstract available


  27. MIMOTO R, Nihira NT, Hirooka S, Takeyama H, et al
    Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Cancer Lett. 2016 Oct 13. pii: S0304-3835(16)30627.
    PubMed     Text format     Abstract available


  28. TU M, Lu C, Lv N, Wei J, et al
    Vasohibin 2 promotes human luminal breast cancer angiogenesis in a non-paracrine manner via transcriptional activation of fibroblast growth factor 2.
    Cancer Lett. 2016 Oct 1. pii: S0304-3835(16)30573.
    PubMed     Text format     Abstract available


    September 2016
  29. DI MODICA M, Regondi V, Sandri M, Iorio MV, et al
    Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30555.
    PubMed     Text format     Abstract available


  30. XU J, Han M, Shen J, Guan Q, et al
    2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30553.
    PubMed     Text format     Abstract available


  31. ZHU J, Zhou Q, Tan S
    Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30563.
    PubMed     Text format     Abstract available


  32. ZHANG Y, Zhang J, Liu C, Du S, et al
    Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Cancer Lett. 2016 Sep 2. pii: S0304-3835(16)30511.
    PubMed     Text format     Abstract available


    July 2016
  33. MARZEC KA, Martino-Echarri E, Irminger-Finger I, Henderson BR, et al
    BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.
    Cancer Lett. 2016 Jul 28. pii: S0304-3835(16)30453.
    PubMed     Text format     Abstract available


  34. PLUCHINO LA, Choudhary S, Wang HR
    Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
    Cancer Lett. 2016 Jul 28. pii: S0304-3835(16)30455.
    PubMed     Text format     Abstract available


  35. GARI HH, DeGala GD, Ray R, Lucia MS, et al
    PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
    Cancer Lett. 2016;380:505-512.
    PubMed     Text format     Abstract available


  36. PAVLOPOULOU A, Oktay Y, Vougas K, Louka M, et al
    Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
    Cancer Lett. 2016;380:485-493.
    PubMed     Text format     Abstract available


  37. UGOLKOV A, Gaisina I, Zhang JS, Billadeau DD, et al
    GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Cancer Lett. 2016 Jul 14. pii: S0304-3835(16)30400.
    PubMed     Text format     Abstract available


  38. ROSSETTI S, Bshara W, Reiners JA, Corlazzoli F, et al
    Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer.
    Cancer Lett. 2016 Jul 13. pii: S0304-3835(16)30397.
    PubMed     Text format     Abstract available


  39. WU J, Ding Y, Chen CH, Zhou Z, et al
    A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
    Cancer Lett. 2016 Jul 4. pii: S0304-3835(16)30393.
    PubMed     Text format     Abstract available


    June 2016
  40. LI XQ, Lu JT, Tan CC, Wang QS, et al
    RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization.
    Cancer Lett. 2016 Jun 15. pii: S0304-3835(16)30367.
    PubMed     Text format     Abstract available


  41. BAPU D, Runions J, Kadhim M, Brooks SA, et al
    N-acetylgalactosamine glycans function in cancer cell adhesion to endothelial cells: A role for truncated O-glycans in metastatic mechanisms.
    Cancer Lett. 2016;375:367-74.
    PubMed     Text format     Abstract available


  42. CHEN KH, Walker AM
    Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.
    Cancer Lett. 2016;375:293-302.
    PubMed     Text format     Abstract available


    May 2016
  43. KIM JY, Cho Y, Oh E, Lee N, et al
    Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
    Cancer Lett. 2016 May 26. pii: S0304-3835(16)30339.
    PubMed     Text format     Abstract available


  44. SASAKI S, Baba T, Nishimura T, Hayakawa Y, et al
    Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis.
    Cancer Lett. 2016;378:23-32.
    PubMed     Text format     Abstract available


  45. NUTA O, Somaiah N, Boyle S, Chua ML, et al
    Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
    Cancer Lett. 2016;374:324-30.
    PubMed     Text format     Abstract available


    April 2016
  46. REN Y, Zhou X, Liu X, Jia HH, et al
    Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
    Cancer Lett. 2016;374:96-106.
    PubMed     Text format     Abstract available


    March 2016
  47. JACOB J, Favicchio R, Karimian N, Mehrabi M, et al
    LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.
    Cancer Lett. 2016;372:137-46.
    PubMed     Text format     Abstract available


  48. JAKHAR R, Paul S, Bhardwaj M, Kang SC, et al
    Astemizole-Histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis.
    Cancer Lett. 2016;372:89-100.
    PubMed     Text format     Abstract available


  49. XU Z, Wang Z, Jia X, Wang L, et al
    MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Cancer Lett. 2016;372:118-27.
    PubMed     Text format     Abstract available


    February 2016
  50. KAWPRASERTSRI S, Pietras RJ, Marguez-Garban DC, Boonyaratanakornkit V, et al
    Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.
    Cancer Lett. 2016 Feb 15. pii: S0304-3835(16)30068.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: